Circulating hsa_circ_0072309, acting via the miR-100/ACKR3 pathway, maybe a potential biomarker for the diagnosis, prognosis, and treatment of brain metastasis from non-small-cell lung cancer.

BACKGROUND: One of the main causes of lung cancer-related death is brain metastasis (BM). Finding early indicators of BM derived from lung cancer is crucial. Therefore, this study was designed to determine if serum hsa_circ_0072309 may be employed as a potential biomarker for BM induced by non-small-cell lung cancer (NSCLC) and to understand its possible underlying mechanism. METHODS: Primary lung cancer and healthy neighboring tissues were obtained from all patients, while BM tissues were taken from BM+ patients. Serum specimens were collected from all patients and healthy volunteers. Hsa_circ_001653, miR-100, and ACKR3 RNA expressions were analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and atypical chemokine receptor 3 (ACKR3) protein expression by western blotting (WB), immunohistochemistry (IHC), and enzyme-linked immunosorbent assay (ELISA). In order to examine the effect of serum hsa_circ_0072309 and its relevant mechanism on BM development, an NSCLC-associated BM model in mice was established. RESULTS: According to the results, miR-100 expression was down-regulated in primary lung cancer tissues compared to healthy lung tissues in all NSCLC patients, and circ_0072309 and ACKR3 expression were up-regulated. In BM tissues compared with primary lung tumors of BM+ patients, in serum samples from all patients compared to healthy volunteers, and in lung tumors of BM+ patients compared to those from BM- patients. Patients' serum exhibits the same level of hsa_circ_0072309/miR-100/ACKR3 expression as in BM samples. Advanced tumor-node-metastasis (TNM) stage, higher BM, shorter post-operative overall survival (OS), and progression-free survival (PFS) are all substantially associated with increased serum circ_0072309 levels in BM+ patients. In animal models, serum owning hsa_circ_0072309 from BM+ patients facilitates BM formation by regulating the miR-100/ACKR3 pathway. CONCLUSIONS: The current preliminary research reveals serum hsa_circ_0072309 as a possible biomarker and target for early diagnosis, prognosis, and therapy of NSCLC-derived BM and suggests a substantial role for the hsa_circ_0072309/miR-100/ACKR3 axis in the formation of BM from NSCLC.

Reversible Growth of Halide Perovskites via Lead Oxide Hydroxide Nitrates Anchored Zeolitic Imidazolate Frameworks for Information Encryption and Decryption.

The low formation energies of metal halide perovskites endow them with potential luminescent materials for applications in information encryption and decryption. However, reversible encryption and decryption are greatly hindered by the difficulty in robustly integrating perovskite ingredients into carrier materials. Here, we report an effective strategy to realize information encryption and decryption by reversible synthesis of halide perovskites, on the lead oxide hydroxide nitrates (Pb13O8(OH)6(NO3)4) anchored zeolitic imidazolate framework composites. Benefiting from the superior stability of ZIF-8 in combination with the strong bond between Pb and N evidenced by X-ray absorption spectroscopy and X-ray photoelectron spectroscopy, the as-prepared Pb13O8(OH)6(NO3)4-ZIF-8 nanocomposites (Pb-ZIF-8) can withstand common polar solvent attack. Taking advantage of blade-coating and laser etching, the Pb-ZIF-8 confidential films can be readily encrypted and subsequently decrypted through reaction with halide ammonium salt. Consequently, multiple cycles of encryption and decryption are realized by quenching and recovery of the luminescent MAPbBr3-ZIF-8 films with polar solvents vapor and MABr reaction, respectively. These results provide a viable approach to integrate the state-of-the-art materials perovskites and ZIF for applications in information encryption and decryption films with large scale (up to 6 × 6 cm2), flexibility, and high resolution (approximate 5 µm line width).

Systemic Corticosteroid Administration in Coronavirus Disease 2019 Outcomes: An Umbrella Meta-Analysis Incorporating Both Mild and Pulmonary Fibrosis-Manifested Severe Disease.

Background: Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed. The real role of corticosteroid use in COVID-19 has long been of interest and is disputable. Methods: We aimed to quantitatively reevaluate the efficacy of corticosteroids on COVID-19. Databases were searched for eligible meta-analyses/systematic reviews with available outcome data. For each association, we estimated the summary effect size with fixed- and random-effects models, 95% confidence intervals, and 95% prediction intervals. Heterogeneity, Egger's test, evidence of small-study effects and excess significance bias, and subgroup analyses were rigorously evaluated. Results: Intended outcomes of 12 eligible studies were mortality, clinical improvement, hospitalization, mechanical ventilation (MV), adverse events (AEs), intensive care unit (ICU) stay, hospital stay, virus clearance time (VCT), and negative conversion. Corticosteroid administration was associated with a 27% risk reduction in MV [hazard ratio (HR): 0.73 (0.64-0.83)] and a 20% reduction in mortality of critically ill/severe COVID-19 patients [HR: 0.80 (0.65-0.98)]. Interestingly, shorter ICU stays and, conversely, potentially longer hospital stays, a longer VCT, and a longer time to negative conversion were associated with corticosteroid use. There was no significant impact of different corticosteroid doses on mortality. Only one study showed slightly excess significant bias. Caution should be applied given the weak nature of the evidence, and it has been confirmed by sensitivity analyses too. Conclusion: This umbrella study found benefits from corticosteroids on MV and especially the mortality of critically ill/severe patients with shorter ICU stays but prolonged hospital stays and VCT. The benefits and harms should be reevaluated and balanced before corticosteroids are cautiously prescribed in clinical practice.

The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.

WHAT IS KNOWN AND OBJECTIVE: Although immune checkpoint inhibitors (ICIs) have shown clinical benefit for patients with non-small cell lung cancer (NSCLC), the efficacy of the combination of ICIs targeting different pathways is still unclear. We performed this meta-analysis to explore the efficacy of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor plus programmed cell death 1 receptor (PD-1)/programmed cell death receptor ligand 1 (PD-L1) inhibitor therapy (CP) for NSCLC IIIB/IV patients. METHODS: We systematically searched the main databases for relevant studies. The main outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS AND DISCUSSION: We identified 3526 articles, including 5 randomized controlled trials (RCTs) (4377 patients), in our meta-analysis. We conducted two comparisons of CP versus chemotherapy or PD1/PDL1 inhibitor (P). Compared with chemotherapy, CP was more effective, with better OS (hazard ratio [HR]: 0.77, 95% CI [confidence interval]: 0.66-0.91; p = 0.001), better PFS (HR: 0.77, 95% CI: 0.70-0.85; p < 0.00001) and comparable objective response rate (ORR) (risk ratio [RR]: 1.27, 95% CI: 0.98-1.65; p = 0.07); in terms of toxicity, CP was comparable to chemotherapy across all-grade adverse events (AEs) (RR: 0.87, 95% CI: 0.73-1.03; p = 0.11) and grade 3-5 AEs (RR: 0.85, 95% CI: 0.63-1.14; p = 0.27). Compared with P, CP had no superiority in efficacy in terms of the OS (HR: 1.04, 95%CI: 0.86-1.24; p=0.70), PFS (HR: 0.95, 95%CI: 0.75-1.22; p = 0.70) and the ORR (RR: 1.07, 95% CI: 0.95-1.21; p = 0.27) but CP was more effective than P when PD-L1 expression was <1% (RR: 0.77,95%CI: 0.60-0.98; p = 0.04); in terms of toxicity, CP was associated with increased all-grade AEs (RR:1.07, 95% CI: 0.97-1.19; p = 0.18) and grade 3-5 AEs (RR:1.58, 95% CI: 1.21-2.07; p = 0.0008). WHAT IS NEW AND CONCLUSION: CP is a beneficial therapeutic schedule with longer PFS and OS than chemotherapy and has an acceptable, manageable grade 3-4 AE rate in IIIB/IV NSCLC. However, compared with P, CP results in better OS only in patients with PD-L1 expression <1%.

Temperature-Assisted Crystal Growth of Photovoltaic α-Phase FAPbI3 Thin Films by Sequential Blade Coating.

Formamidinium lead triiodide (FAPbI3) exhibits the smallest band gap among lead halide perovskites, which is more desirable for solar cell applications compared to methylammonium-based counterparts. However, it remains a big challenge to prepare phase-pure α-FAPbI3 in addition to controlling the crystal morphology during film formation. Herein, we developed a temperature-assisted crystal growth to prepare high-quality thin films of α-FAPbI3 by sequential blade coating. It is found that depositing organic cation FAI at elevated temperatures facilitates the growth of α-FAPbI3, which otherwise yields mainly a yellow δ-phase at room temperature. In parallel, the crystal morphology of the perovskite films can be effectively manipulated by taking advantage of the porous structure of PbI2. Solar cells prepared with the blade-coated α-FAPbI3 yield a champion efficiency of 18.41%, which is among the highest values for FAPbI3-only solar devices. These results suggest that two-step sequential blade deposition offers a viable approach to fabricate high-quality α-FAPbI3 films for optoelectronic applications.

A Critical Review on Crystal Growth Techniques for Scalable Deposition of Photovoltaic Perovskite Thin Films.

Although the efficiency of small-size perovskite solar cells (PSCs) has reached an incredible level of 25.25%, there is still a substantial loss in performance when switching from small size devices to large-scale solar modules. The large efficiency deficit is primarily associated with the big challenge of coating homogeneous, large-area, high-quality thin films via scalable processes. Here, we provide a comprehensive understanding of the nucleation and crystal growth kinetics, which are the key steps for perovskite film formation. Several thin-film crystallization techniques, including antisolvent, hot-casting, vacuum quenching, and gas blowing, are then summarized to distinguish their applications for scalable fabrication of perovskite thin films. In viewing the essential importance of the film morphology on device performance, several strategies including additive engineering, Lewis acid-based approach, solvent annealing, etc., which are capable of modulating the crystal morphology of perovskite film, are discussed. Finally, we summarize the recent progress in the scalable deposition of large-scale perovskite thin film for high-performance devices.

High-frequency oscillatory ventilation combined with partial liquid ventilation in experimental lung injury: effects on lung cell apoptosis.

OBJECTIVE: To investigate the effects of high-frequency oscillatory ventilation (HFOV) and partial liquid ventilation (PLV) on apoptosis of lung tissue induced by steam inhalation injury in rabbit. DESIGN: A prospective, randomized, controlled, multiple-group study. SETTING: An animal research laboratory centre in a university burns centre. SUBJECTS: New Zealand rabbits (n = 32; 2.25 ± 0.25 kg) of either sex. INTERVENTIONS: The animals were ventilated by HFOV with a mean airway pressure of 10 cm H2O, a frequency of 10 Hz, an amplitude of 20 cm H2O, an inspiratory:expiratory ratio of 1:1, and an FiO2 of 1.0. After the induction of acute lung injury (ALI) by steam inhalation, the animals were randomly divided into four groups: CMV, HFOV, CMV + PLV, HFOV + PLV group. Then they were ventilated for 4 h by CMV, HFOV, CMV + PLV and HFOV + PLV, respectively. After the experimental period, cell apoptosis and apoptosis indexes in the lung tissue were assessed with TUNEL FragELTM (Fragment End Labeling). RESULTS: Lung tissue apoptosis indexes in HFOV group and HFOV + PLV group were lower than that of in CMV group and CMV + PLV group; between-group comparison had significant difference (P < 0.01). HFOV + PLV group showed lowest apoptosis indexes. CONCLUSION: HFOV combined with PLV can suppress lung tissue apoptosis induced by steam inhalation.

Humoral immunity-mediated chronic rejection in liver transplantation is associated with predominant IL-10 expression.

Chronic rejection is a major cause of graft dysfunction and retransplantation after liver allotransplantation. Recent studies have implicated humoral response in this chronic rejection reaction. However, the manner in which humoral response is activated has not been fully investigated. In the present study, we address this question using our previously established chronic allograft liver rejection model induced by low-dose immunosuppressive cyclosporine (CsA) following Dark Agouti (DA) to Brown Norway (BN) liver transplantation. High-level donor-specific antibodies (IgG1 isotype), C4d deposition and histological graft damage indicated the involvement of humoral rejection in this chronic rejection reaction. In vitro assay showed that alloantibodies from pre-sensitized BN recipients induced apoptosis of bile ductal cells isolated from donor livers and the production of pro-fibrosis factors (TGF-beta, PDGF and FGF). Statistical analysis showed that the serum level of IL-10 was positively correlated with that of donor-specific antibodies (IgG1 isotype). Blockade of IL-10 in vivo down-regulated the level of donor-specific antibodies and ameliorated the outcome of chronic rejection. This suggests that humoral response in chronic allograft liver rejection is associated with Th2 type cytokine IL-10 and that Th2 response might promote chronic rejection by inducing a humoral response.